Clinical Significance of p53, K-ras, and Ki-67 Expression in Cancer and Dysplastic Tissues in Patients with Extrahepatic Bile Duct Cancer

초록

Background/Aims : We examined differences in the expression of p53, K-ras, and Ki-67 between Extrahepatic bile duct (EHBD) carcinoma, dysplasia, hyperplasia, and normal tissues and determined their clinical significance. We also investigated if dysplasia or hyperplasia is the precancerous lesion in EHBD carcinoma. Methods: Specimens of 23 patients with surgically resected EHBD carcinoma were classified into normal, hyperplasia, dysplasia, and carcinoma and immunostained with p53, K-ras, and Ki-67 antibody. Results: p53 was expressed in normal, hyperplasia, dysplasia, and carcinoma in 0%, 0%, 46.7%, and 66.7%, respectively. K-ras was positive in 0%, 0%, 46.7%, and 55.6%, respectively. Ki-67 was positive in 0%, 18.1%, 73.3%, and 100%, respectively. There was no significant correlation between p53 immunoreactivity and gender, histological grade, stage of EHBD carcinoma, and survival but p53 positive patients were older than p53 negative patients. K-ras and Ki-67 immunoreactivity was not associated with gender, age, histological grade, and stage of EHBD carcinoma, and survival. Conclusion: These data suggest that p53 and K-ras mutations may have a role in the carcinogenesis of EHBD carcinoma and that dysplasia may be a precancerous lesion of EHBD carcinoma. Ki-67 may be useful in differentiation of carcinoma from dysplasia. We found no prognostic significance of p53, K-ras, Ki-67 expression in clinical parameters.